Zirconium silicate - ZS Pharma

Drug Profile

Zirconium silicate - ZS Pharma

Alternative Names: LOKELMA; Lokelma; Sodium zirconium cyclosilicate; UXSi-9; Ziconite; Zircon; ZS; ZS 9

Latest Information Update: 24 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ZS Pharma
  • Class Heavy metals; Minerals; Silicates; Transition elements
  • Mechanism of Action Potassium binding modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Registered Hyperkalaemia

Most Recent Events

  • 22 May 2018 AstraZeneca plans the PRIORITIZE HF phase II trial for Heart Failure in USA, Brazil, Canada, Hungary, Romania and Russia , (NCT03532009)
  • 21 May 2018 Registered for Hyperkalaemia (In adults) in USA (PO)
  • 18 May 2018 AstraZeneca plans the HARMONIZE Asia phase III trial for Hyperkalaemia in China , (NCT03528681)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top